• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Neutrophil to lymphocyte ratio is predictive of severe complications and mortality in patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective longitudinal observational study.

作者信息

Sugiyama Seiko, Yamamoto Takenobu, Aoyama Yumi

机构信息

Department of Dermatology, Kawasaki General Medical Center, Kawasaki Medical School, Okayama, Okayama, Japan; Department of Dermatology, Kawasaki Medical School, Kurashiki, Okayama, Japan.

Department of Dermatology, Kawasaki Medical School, Kurashiki, Okayama, Japan.

出版信息

J Am Acad Dermatol. 2022 Jun;86(6):1387-1390. doi: 10.1016/j.jaad.2021.05.043. Epub 2021 May 29.

DOI:10.1016/j.jaad.2021.05.043
PMID:34058280
Abstract
摘要

相似文献

1
Neutrophil to lymphocyte ratio is predictive of severe complications and mortality in patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective longitudinal observational study.中性粒细胞与淋巴细胞比值可预测二肽基肽酶-4抑制剂相关大疱性类天疱疮患者的严重并发症和死亡率：一项回顾性纵向观察研究。
J Am Acad Dermatol. 2022 Jun;86(6):1387-1390. doi: 10.1016/j.jaad.2021.05.043. Epub 2021 May 29.
2
Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor.与使用二肽基肽酶-4抑制剂相关的大疱性类天疱疮。
CMAJ. 2022 May 24;194(20):E705. doi: 10.1503/cmaj.211933.
3
Dipeptidyl Peptidase-4 Inhibitor Induced Bullous Pemphigoid Complicated by Acquired Reactive Perforating Dermatosis.二肽基肽酶-4抑制剂诱发大疱性类天疱疮并伴有获得性反应性穿通性皮病
Actas Dermosifiliogr. 2022 Oct;113(9):914-915. doi: 10.1016/j.ad.2021.01.023. Epub 2022 May 27.
4
[Association between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors and impact of their withdrawal].大疱性类天疱疮与二肽基肽酶-4抑制剂之间的关联及其撤药的影响
Aten Primaria. 2023 Apr;55(4):102586. doi: 10.1016/j.aprim.2023.102586. Epub 2023 Feb 24.
5
Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.病例报告：二肽基肽酶-4 抑制剂相关性大疱性类天疱疮发病后出现多种疾病特异性抗体
Front Immunol. 2022 Mar 3;13:843480. doi: 10.3389/fimmu.2022.843480. eCollection 2022.
6
Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.二肽基肽酶-4 抑制剂致大疱性类天疱疮的风险异质性：一项基于日本后期高龄者医疗数据库的人群队列研究。
J Diabetes Investig. 2023 Jun;14(6):756-766. doi: 10.1111/jdi.14004. Epub 2023 Mar 10.
7
Clinical and immunological characterization of 14 cases of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: a single-centre study.14例二肽基肽酶-4抑制剂相关大疱性类天疱疮的临床和免疫学特征：一项单中心研究
Br J Dermatol. 2020 Mar;182(3):806-807. doi: 10.1111/bjd.18516. Epub 2019 Nov 24.
8
Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid.合并用药与二肽基肽酶-4抑制剂相关的大疱性类天疱疮。
An Bras Dermatol. 2021 Nov-Dec;96(6):782-784. doi: 10.1016/j.abd.2020.10.010. Epub 2021 Sep 30.
9
Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus.二肽基肽酶-4抑制剂相关的大疱性类天疱疮：100例大疱性类天疱疮合并糖尿病患者的对比研究
J Dermatol. 2021 Apr;48(4):486-496. doi: 10.1111/1346-8138.15778. Epub 2021 Feb 4.
10
Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.日本二肽基肽酶-4 抑制剂相关性大疱性类天疱疮的临床特征：一项全国性回顾性观察研究。
J Dermatol. 2022 Jul;49(7):697-702. doi: 10.1111/1346-8138.16394. Epub 2022 Apr 27.

引用本文的文献

1
Adaptive and innate immune pathogenesis of bullous pemphigoid: A review.大疱性类天疱疮的适应性和固有免疫发病机制：综述。
Front Immunol. 2023 Mar 10;14:1144429. doi: 10.3389/fimmu.2023.1144429. eCollection 2023.
2
Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions.抗巨细胞病毒治疗：是否以及何时开始，这些都是问题。
Pharmaceuticals (Basel). 2022 Jun 27;15(7):797. doi: 10.3390/ph15070797.